Abstract:Abnormalities in B cells play pivotal roles in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). Breach in central and peripheral tolerance mechanisms generates autoreactive B cells which contribute to the pathogenesis of SLE and LN. Dysregulation of B cell transcription factors, cytokines and B cell-T cell interaction can result in aberrant B cell maturation and autoantibody production. These immunological abnormalities also lead to perturbations in circulating and infiltrating B cells in SLE and LN patients. Conventional and novel immunosuppressive medications confer differential effects on B cells which have important clinical implications. While cyclophosphamide and mycophenolate mofetil (MMF) showed comparable clinical efficacy in active LN, MMF induction was associated with earlier reduction in circulating plasmablasts and plasma cells. Accumulating evidence suggests that MMF maintenance is associated with lower risk of disease relapse than azathioprine, which may be explained by its more potent and selective suppression of B cell proliferation. Novel therapeutic approaches targeting the B cell repertoire include B cell depletion with monoclonal antibodies binding to cell surface markers, inhibition of B cell cytokines, and modulation of costimulatory signals in B cell-T cell interaction. These biologics, despite showing improvements in serological parameters and proteinuria, did not achieve primary endpoints when used as add-on therapy to standard treatments in active LN patients. Other emerging treatments such as calcineurin inhibitors, mammalian target of rapamycin inhibitors and proteasome inhibitors also show distinct inhibitory effects on the B cell repertoire. Advancement in the knowledge on B cell biology has fueled the development of new therapeutic strategies in SLE and LN. Modification in background treatments, study endpoints and selective recruitment of subjects showing aberrant B cells or its signaling pathways when designing future clinical trials may better elucidate the roles of these novel therapies for SLE and LN patients.

The Role of Pathogenic B-Cell Clones in Antibody Mediated Autoimmune Disorders

B Cell Activation and Autoantibody Production in Autoimmune Diseases.

B Cells in Autoimmune Diseases

Targeting B Cells and Plasma Cells in Autoimmune Diseases

B cell dysregulation and depletion therapy in primary membranous nephropathy: Prospects and potential challenges

B cell depletion therapy in autoimmune diseases.

Epigenetic Regulation of B Cells and Its Role in Autoimmune Pathogenesis

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

Role of canonical and noncanonical autophagy pathways in shaping the life journey of B cells

B cell-targeted therapies in autoimmunity: rationale and progress

B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?

CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

[Immunoglobulin Variable Region Gene Rearrangement and Hypermutation in Paraneoplastic Pemphigus Associated Castleman's Tumor].

B-cell depletion in autoimmune diseases

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

B Cell Modulation Strategies in Autoimmune Diseases: New Concepts

[A Clinicopathological Study of Castleman's Disease].

B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments

Translational Mini‐Review Series on B Cell‐Directed Therapies: The pathogenic role of B cells in autoantibody‐associated autoimmune diseases – lessons from B cell‐depletion therapy

B-cell-directed therapies for autoimmune disease